NorthWest Biotherapeutics Inc (NWBO)

[no2koolaid]

Many thanks for the response and allow me to say that your analysis would be interesting to see. While DCF is good, it is limited (it does not consider the full value of all assets) and my effort was limited to using a surrogate for NWBO (Keytruda).

Your E/V analysis is intriguing (for those unaware, it covers more than DCF), and that you tied it to n/rGBM in developed countries (I assume that includes the EMA covered countries) is very cool. That, sir, is well done. And while not asking for a number, your analysis provides you a prospective value of DCVax that, as you stated, shows the significant potential for NWBO.

In case anyone is interested, here is a link that discusses a range (NOT THE range) of best practices for biotech/pharma valuations that would be of the types done by the business development people that sit in the finance depts of the BP firms...and do it for a living.

https://www.biopharmavantage.com/pharma-biotech-valuation-best-practices

Cheers!